Combining FLT3 and SYK inhibition for AML

Combining FLT3 and SYK inhibition for AML

VJHemOnc

2 years
139 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
TAK-659 is a novel FLT3 inhibitor in the initial trial stages for the treatment of acute myeloid leukemia (AML). Interestingly, TAK-659 also inhibits SYK, a target that is more common in the treatment of B-cell malignancies. In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the pharmacokinetics and promising preliminary results of the Phase I trial of this agent (NCT02323113) in patients with relapsed or refractory AML. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Up Next Autoplay